Patent Claims

1. Pharmaceutical formulation, containing a xanthogenate of formula I



(I)

wherein R_1 represents an optionally substituted aryl or alkyl residue, and R_2 represents a metal atom, an optionally substituted alkyl, alkoxy, amino or ammonium group or halogen,
and an inhibitor of viral nucleic acid replication, and optionally an adjuvant enhancing the activity of the xanthogenate and a carrier substance reducing the irritating effect.

2. Pharmaceutical formulation according to claim 1, **characterized in that** R_1 is an adamantyl, norbornyl, tricyclodecyl, benzyl, linear or branched C_3-C_{20} alkyl, C_3-C_{20} cycloalkyl, furyl, pyridyl, anthracyl, naphthyl, phenanthryl, perinaphthyl or quinuclidinyl residue, whereby the aforementioned linear or branched C_3-C_{20} alkyl residue can be substituted by a hydroxyl, a C_1-C_4 alkoxy group, a halogen atom or an amino group, and the aforementioned C_3-C_{20} cycloalkyl residue can also be substituted by a hydroxyl, a C_1-C_4 alkoxy or a C_1-C_4 alkyl group, a halogen atom or an amino group.

3. Pharmaceutical formulation according to claim 2, **characterized in that** R_1 is a cyclododecyl, dodecyl, undecyl, decyl, tricyclo[5,2,1,$0^{2,6}$]-decyl, nonyl, octyl, bicyclo[2,2,1]-heptyl, cyclohexyl, hexyl or toluyl residue.

4. Pharmaceutical formulation according to any one of the claims 1 to 3, **characterized in that** R_2 is a sodium or potassium atom or a dimethylglycylester or methylester group.

5. Pharmaceutical formulation according to any one of the claims 1 to 4, **characterized in that** the inhibitor of viral nucleic acid replication is a nucleoside analogue.

6. Pharmaceutical formulation according to claim 5, **characterized in that** the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.

7. Pharmaceutical formulation according to any one of the preceding claims, **characterized in that** it contains 1 to 10, preferably 2 to 4 parts inhibitor of viral nucleic acid replication per one part xanthogenate.

8. Pharmaceutical formulation according to any one of the claims 1 to 7, **characterized in that** it contains an ionic detergent as adjuvant, preferably a fatty acid with 6 to 19 C atoms or an alkylsulphate with 8 to 18 C atoms.

9. Pharmaceutical formulation according to any one of the claims 1 to 7, **characterized in that** it contains deoxycholic acid or a pharmaceutically tolerable salt thereof as adjuvant.

10. Pharmaceutical formulation according to any one of the claims 1 to 7, **characterized in that** it contains a phosphonic acid as adjuvant.

11. Pharmaceutical formulation according to claims 1 to 10, **characterized in that** it contains, in addition, cholesterol as carrier substance.

12. Agent for the treatment of viral, tumor or autoimmune diseases, **characterized in that** it contains a pharmaceutical formulation according to at least one of the claims 1 to 11.

13. Agent according to claim 12, **characterized in that** it contains tricyclo[5,2,1,$0^{2,6}$]-decane-9-yl-xanthogenate as xanthogenate, cholesterol or phosphatidylcholine as carrier substance, the sodium or potassium salt of decanoic acid as adjuvant, and the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.

14. Agent according to claim 13, **characterized in that** it contains aciclovir as inhibitor of viral nucleic acid replication.

15. Agent according to at least one of the claims 12 to 14, **characterized in that** it contains one part xanthogenate, one part inhibitor of viral nucleic acid replication, four parts carrier substance, and one part adjuvant.

16. Agent according to at least one of the claims 12 to 14, **characterized in that** it is an ointment that contains the pharmaceutical formulation in a lipophilic substance, preferably vaseline.